Pictet Asset Management Holding SA Increases Position in AbbVie Inc. $ABBV

Pictet Asset Management Holding SA lifted its stake in AbbVie Inc. (NYSE:ABBV) by 2.2% in the 1st quarter, Holdings Channel reports. The firm owned 1,173,729 shares of the company’s stock after purchasing an additional 25,003 shares during the quarter. Pictet Asset Management Holding SA’s holdings in AbbVie were worth $255,224,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Braun Stacey Associates Inc. lifted its position in shares of AbbVie by 1.8% during the 1st quarter. Braun Stacey Associates Inc. now owns 84,259 shares of the company’s stock valued at $18,325,000 after acquiring an additional 1,471 shares during the period. Welch Financial Planning LLC lifted its stake in AbbVie by 22.0% in the 1st quarter. Welch Financial Planning LLC now owns 2,326 shares of the company’s stock valued at $506,000 after buying an additional 419 shares in the last quarter. Rooted Wealth Advisors Inc. lifted its stake in AbbVie by 23.3% in the 1st quarter. Rooted Wealth Advisors Inc. now owns 1,187 shares of the company’s stock valued at $242,000 after buying an additional 224 shares in the last quarter. Narus Financial Partners LLC increased its position in AbbVie by 9.7% during the first quarter. Narus Financial Partners LLC now owns 2,309 shares of the company’s stock worth $502,000 after buying an additional 205 shares in the last quarter. Finally, Lewis Asset Management LLC raised its holdings in shares of AbbVie by 16.0% in the first quarter. Lewis Asset Management LLC now owns 13,589 shares of the company’s stock worth $2,956,000 after acquiring an additional 1,877 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 3.4%

Shares of NYSE:ABBV opened at $251.52 on Friday. The company has a fifty day simple moving average of $215.16 and a 200 day simple moving average of $219.18. The firm has a market cap of $444.38 billion, a PE ratio of 123.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $253.35.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.46 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is presently 340.89%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company set a $260.00 target price on AbbVie in a report on Monday, June 22nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.81.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.